Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. (Q33383835)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. |
scientific article |
Statements
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors (English)
Noboru Yamamoto
Tomohide Tamura
Nobuyuki Yamamoto
Kazuhiko Yamada
Yasuhide Yamada
Hiroshi Nokihara
Toshiaki Takahashi
Haruyasu Murakami
Narikazu Boku
Kentaro Yamazaki
Thomas A Puchalski